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The relationship between the systemic inflammatory response (as evidenced by elevated C-reactive protein and lowered albumin
concentrations), clinico-pathologic status and relapse-free, cancer-specific and overall survival was examined in patients with invasive
primary operable breast cancer (n¼300). The median follow-up of the survivors was 46 months. During this period, 37 patients
relapsed and 25 died of their cancer. On multivariate analysis, only tumour size (Po0.05), albumin (Po0.01) and systemic treatment
(Po0.0001) were significant independent predictors of relapse-free, cancer-specific and overall survival. Lower serum albumin
concentrations (p43gl
 1) were associated with deprivation (Po0.05), hormonal receptor negative tumours (Po0.01) and
significantly poorer 3-year relapse-free (85 vs 93%, P¼0.001) cancer-specific (87 vs 97%, Po0.0001) and overall survival (84 vs 94%,
P¼0.001) rates. The results of the present study suggest that lower preoperative albumin concentrations, but not elevated
C-reactive protein concentrations, predict relapse-free, cancer-specific and overall survival, independent of clinico-pathologic status
and treatment in patients undergoing potentially curative surgery for primary operable breast cancer.
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Breast cancer is the commonest female malignancy and is a major
cause of morbidity and mortality in the Western World. For
example, in the UK, there are approximately 42000 new patients
each year and almost 13000 deaths attributable to the disease
(CancerStats, 2003).
It is increasingly recognised that variations in outcome in cancer
patients are not solely determined by the characteristics of the
tumour but also by the host-response factors (Balkwill and
Mantovani, 2001; Coussens and Werb, 2002). However, the
tumour–host interaction is complex and has yet to be fully
understood. It is now accepted that the host systemic inflamma-
tory response can be assessed by examining the changes in the
concentrations of acute phase proteins, such as elevated circulating
concentrations of C-reactive protein and low concentrations of
albumin (Gabay and Kushner, 1999). It is of interest that, either
singly or combined, these factors have been shown to be stage
independent prognostic factors in patients with a variety of
advanced cancers (McMillan et al, 2001; Mahmoud and Rivera,
2002; Forrest et al, 2003; Crumley et al, 2006a,b).
There is also some evidence that the systemic inflammatory
response has prognostic value in patients with metastatic breast
cancer. For example, previous studies have reported that the
presence of elevated circulating concentrations of C-reactive
protein (Williams et al, 1990; Albuquerque et al, 1995; Zhang
and Adachi, 1999; Al Murri et al, 2006) and low concentrations of
albumin (Heys et al, 1998; Al Murri et al, 2006) are associated with
poorer survival.
However, few studies have examined the prognostic value of the
systemic inflammatory response in patients with primary breast
cancer (Mortensen and Rudczynski, 1982; Lis et al, 2003). Those
studies that have, appear to have produced conflicting results with
regard to whether C-reactive protein or albumin concentrations
have independent prognostic value. For example, Mortensen and
Rudczynski (1982) studied almost 300 patients with a follow-up
period of 3–48 months post-surgery and reported that the
presence of an elevated C-reactive protein concentrations was
not an independent prognostic factor. In contrast, Lis et al (2003)
reported that in almost 200 patients with a follow-up period of 6–
84 months, albumin was a stage independent prognostic factor.
However, in both these studies, median follow-up was limited and
approximately 20% of patients studied had advanced disease.
Therefore, the prognostic value of C-reactive protein and
albumin in patients with primary operable breast cancer remains
unclear. The aim of the present study was to examine the
relationship between clinico-pathologic status, C-reactive protein
and albumin concentrations, measured before surgery and cancer-
specific survival in patients with invasive primary operable breast
cancer.
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Three hundred patients presenting with invasive primary operable
breast cancer to two hospitals (Western Infirmary, Glasgow and
Wishaw General Hospital, Lanarkshire) in the West of Scotland
between June 2001 and July 2003 were prospectively included in
the study.
The extent of deprivation was derived from the 1991 census,
using the postcode of residence at diagnosis (Carstairs and Morris,
1990, 1991). The results are presented by amalgamating the seven
categories into three groups: affluent (categories 1 and 2),
intermediate (categories 3–5) and deprived (categories 6 and 7).
Clinico-pathological data including age, deprivation category,
histological type, tumour size and grade, lymph node status,
oestrogen (ER) and progesterone receptor status. The type of
surgery and the use of adjuvant treatment (chemotherapy,
hormonal therapy and radiotherapy) was recorded.
Routine preoperative laboratory measurement of C-reactive
protein, albumin and white cell count were carried out. At this
time, no patients showed clinical evidence of infection or other
active chronic inflammatory conditions such as rheumatoid
arthritis or crohn’s disease. The coefficient of variation for these
measurements was less than 10%, as established by routine quality
control procedures. The limit of detection of C-reactive protein
concentration assay was 6mgl
 1, with the upper limit of normal
values being p10mgl
 1.
The study was approved by the local Research Ethics
committees.
Statistics
As appropriate, data are presented as median and range, and
comparisons between patient groups were carried out using the
w
2 test or Mann–Whitney U-test. Statistical analysis was based
on the seven individual deprivation categories. Grouping of the
laboratory variables was carried out using standard thresholds
(Goldwasser and Feldman, 1997; O’Gorman et al, 2000; McMillan
et al, 2001; Maltoni et al, 2005).
The correlation between C-reactive protein, white cell counts
and albumin concentrations was performed using the Spearman’s
Rank correlation. Relapse-free, cancer-specific and overall survival
analyses of the group variables were performed using the Cox
proportional hazard model. Deaths up to the end of May 2006 were
included in the analysis. Multivariate survival analyses, including
all covariates that were significant on univariate analysis, were
performed using a stepwise backward procedure to derive a final
model of the variables that had a significant independent
relationship with survival. To remove a variable from the model,
the corresponding P-value had to be greater than 0.10. Analysis
was performed using SPSS software version 13.0 (SPSS Inc.,
Chicago, IL, USA).
RESULTS
The baseline clinico-pathological characteristics of the patients
with primary operable breast cancer (n¼300) are shown in
Table 1. Two hundred and thirty-three patients (78%) patients
were over 50 years of age; 82 (27%) were in the most deprived
categories 6 and 7.
Of the 300 patients, 254 (85%) patients had ductal carcinoma,
122 (41%) had a tumour larger than 2cm and 130 (43%) had
axillary lymph node involvement. The majority of patients had
tumour grade II/III (81%) disease. Sixty-two (21%) had ER-
negative tumours. Twenty out of 300 (7%) patients had evidence of
pre-existing comorbidity, such as liver dysfunction, cardiovascular
disease or diabetes mellitus. In one patient, this was severe enough
to interfere with planned adjuvant treatment. In all, 288 (96%)
patients received adjuvant treatment in the form of endocrine
therapy and/or chemotherapy.
The majority had a white cell count, albumin and C-reactive
protein concentrations in the normal range (96, 100 and 88%
Table 1 The clinical and pathological characteristics of patients with invasive primary operable breast cancer and survival (relapse-free, cancer-specific and
overall survival)
Relapse-free survival Cancer-specific survival Overall survival
Patients Hazard ratio P-value Hazard ratio P-value Hazard ratio
(n¼300) (95% CI) (95% CI) (95% CI) P-value
Age (p50/450 years) 67/233 2.52 (0.89-7.11) 0.081 1.56 (0.54-4.54) 0.416 2.60 (0.93 – 7.33) 0.070
Deprivation (1–2/3–5/6–7)* 39/179/82 0.93 (0.75–1.14) 0.485 1.01 (0.79–1.31) 0.915 1.10 (0.90–1.36) 0.360
Type (special type/lobular/ductal) 11/35/254 3.09 (0.83–11.55) 0.094 14.97 (0.33–677.82) 0.164 1.23 (0.59–2.60) 0.583
Size (p20/21–50/450mm) 178/117/5 3.29 (1.83–5.94) o0.0001 3.56 (1.74–7.26) o0.0001 2.86 (1.62–5.06) o0.0001
Grade (I/II/III) 56/148/95 2.23 (1.33–3.74) 0.002 2.85 (1.46–5.58) 0.002 1.74 (1.07–2.82) 0.026
Involved lymph node (0/1–3/43) 169/92/38 1.90 (1.25–2.88) 0.003 2.37 (1.44–3.93) 0.001 1.52 (1.01–2.30) 0.046
Hormonal receptor status (ER+ PR+/ER+ PR 
or unknown/ER  PR  or unknown)
116/122/62 2.61 (1.66–4.13) o0.0001 2.76 (1.57–4.85) o0.0001 1.94 (1.26–2.97) 0.002
White cell count (10
9l
 1)** 7.0 (3.4–17.4) 0.97 (0.83–1.15) 0.755 0.94 (0.76–1.16) 0.559 1.04 (0.89–1.21) 0.619




230/53/13 0.81 (0.41–1.60) 0.547 1.07 (0.52–2.21) 0.857 1.36 (0.81–2.29) 0.247
Albumin concentration (gl
 1)** 44 (35–52) 0.88 (0.78–0.99) 0.035 0.82 (0.71–0.94) 0.006 0.88 (0.78–0.98) 0.026
Albumin concentration (443/p43gl
 1) 155/114 3.39 (1.61–7.12) 0.001 5.01 (1.85–13.57) 0.002 3.23 (1.58–6.59) 0.001
C-reactive protein concentration (mgl
 1)** p6( p6–66) 0.96 (0.88–1.04) 0.293 0.97 (0.89–1.06) 0.518 0.97 (0.90–1.04) 0.391
C-reactive protein (p10/410mgl
 1) 265/35 0.40 (0.10–1.68) 0.211 0.62 (0.15–2.65) 0.522 0.60 (0.19–1.95) 0.395
Loco-regional treatment (mastectomy or
conservation surgery+radiotherapy/
mastectomy+radiotherapy)
221/79 3.70 (1.94–7.06) o0.0001 5.51 (2.43–12.48) o0.0001 2.40 (1.27–4.51) 0.007
Systemic treatment (ER-based treatment)
(hormonal/hormonal+chemotherapy/
chemotherapy/none)
150/86/52/9 2.03 (1.43–2.88) o0.0001 2.59 (1.67–4.01) o0.0001 1.93 (1.37–2.73) o0.001
Abbreviations: CI, confidence interval; ER, oestrogen receptor; PR, progesterone receptor. *Individual deprivation categories were used in the statistical analysis and **median
(range).
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srespectively) before surgery. White cell count was correlated with
C-reactive protein (rs¼0.13, P¼0.023) but not albumin concen-
tration (rs¼0.03, P¼0.587). Albumin was correlated with
C-reactive protein concentration (rs¼ 0.19, P¼0.002).
The minimum follow-up was 35 months; the median follow-up
of the survivors was 46 months. During this period, 37 patients
relapsed and 25 died of their cancer; a further 14 patients died of
intercurrent disease.
On univariate survival analysis, age (Po0.10), tumour type
(Po0.10), tumour size (Po0.0001), grade (Po0.01), lymph node
involvement (Po0.01), hormone receptor status (Po0.0001),
albumin (Pp0.001), loco-regional treatment (Po0.0001) and
systemic treatment (Po0.0001) were significantly associated with
relapse-free survival. On multivariate analysis of these significant
covariates, age (HR 5.02, 95%CI 1.49–16.93, P¼0.009), tumour
size (HR 2.34, 95%CI 1.18–4.62, P¼0.015), albumin (HR 3.65,
95%CI 1.71–7.78, P¼0.001), loco-regional treatment (HR 2.56,
95%CI 1.17–5.59, P¼0.019) and systemic treatment (HR 2.26,
95%CI 1.54–3.32, Po0.0001) were significant independent pre-
dictors of relapse-free survival.
On univariate survival analysis, tumour size (Po0.0001),
grade (Po0.01), lymph node involvement (P0p0.001), hormone
receptor status (Po0.0001), albumin (Po0.01), loco-regional
treatment (Po0.0001) and systemic treatment (Po0.0001) were
significantly associated with cancer-specific survival. On multi-
variate analysis of these significant covariates, tumour size
(HR 2.53, 95%CI 1.15–5.55, P¼0.021), albumin (HR 4.44, 95%CI
1.60–12.28, P¼0.004), loco-regional treatment (HR 3.55, 95%CI
1.30–9.67, P¼0.013) and systemic treatment (HR 2.67,
95%CI 1.56–4.57, Po0.0001) were significant independent
predictors of cancer-specific survival.
On univariate survival analysis, age (Po0.10), tumour size
(Po0.0001), grade (Po0.05), lymph node involvement (Po0.05),
hormone receptor status (Po0.01), albumin (Pp0.001), loco-
regional treatment (Po0.01) and systemic treatment (Po0.001)
were significantly associated with overall survival. On multivariate
analysis of these significant covariates, age (HR 4.19, 95%CI 1.26–
13.91, P¼0.019), albumin (HR 3.33, 95%CI 1.60–6.90, P¼0.001),
tumour size (HR 2.48, 95%CI 1.36–4.55, P¼0.003) and systemic
treatment (HR 2.10, 95%CI 1.45–3.05, Po0.0001) were significant
independent predictors of overall survival.
Patients were then grouped according to albumin concentra-
tions (443/p43gl
 1) as shown in Table 2. A lower serum
albumin concentration (p43gl
 1) was associated with deprivation
(Po0.05), hormonal receptor negative tumours (Po0.01) and
significantly poorer 3-year relapse-free (85 vs 93%, P¼0.001),
cancer-specific (87 vs 97%, Po0.0001) and overall survival (84 vs
94%, P¼0.001) rates.
DISCUSSION
Predicting recurrence and survival following potentially curative
surgical resection for primary operable breast cancer is con-
ventionally based on standard clinico-pathological criteria such as
age, tumour size and grade, nodal status and hormonal receptor
status. However, it was of interest that other host-related factors,
such as the systemic inflammatory response, have previously been
shown to be associated with poor survival following a potentially
curative resection for a variety of cancers including gastro-
oesophageal, pancreatic, colorectal and urinary bladder cancers
(McMillan et al, 2003; Hilmy et al, 2005; Jamieson et al, 2005;
Crumley et al, 2006a,b).
In the present study, albumin but not C-reactive protein was a
significant, stage independent, predictor of survival in patients
with primary operable breast cancer. The relationship between
albumin concentrations and outcome are therefore consistent with
those previously reported in patients with advanced breast cancer
(Heys et al, 1998; Al Murri et al, 2006).
Previous studies have shown that elevated C-reactive protein
concentrations have prognostic value in patients with a variety of
primary operable tumours (Ikeda et al, 2003; McMillan et al, 2003;
Hilmy et al, 2005; Jamieson et al, 2005) and also in patients with
advanced breast cancer (Williams et al, 1990; Albuquerque et al,
1995; Zhang and Adachi, 1999; Al Murri et al, 2006). It was
therefore unexpected that C-reactive protein, either as a contin-
uous or categorical variable, was not a significant prognostic factor
in the present study.
Table 2 The clinico-pathological characteristics of patients with invasive primary operable breast cancer according to albumin concentrations
Albumin 443gl
 1 Albumin p43gl
 1
(n¼155) (n¼114) P-value
Age (p50/450 years) 35/120 26/88 0.965
Deprivation (1–2/3–5/6–7)* 26/90/39 13/68/33 0.011
Type (special type/lobular/ductal) 8/17/130 3/15/96 0.524
Size (p20/21–50/450mm) 96/57/2 62/49/3 0.384
Grade (I/II/III) 31/72/52 18/65/30 0.201
Involved lymph node (0/1–3/43) 93/47/15 60/35/18 0.269
Hormonal receptor status (ER+ PR+/ER+ PR  or unknown/ER  PR  or
unknown)
80/47/28 35/54/25 0.002
White cell count (10
9l
 1)** 6.8 (3.6–13.9) 7.0 (3.4–17.4) 0.920
White cell count (o8.5/8.5–11/411 10
9l
 1) 127/18/8 83/27/3 0.281
C- reactive protein (mgl
 1)** o6( o6–57) o6( o6–66) 0.138
C- reactive protein (p10/410mgl
 1) 136/19 102/12 0.660
Loco-regional treatment (mastectomy or conservation surgery+radiotherapy/
mastectomy+radiotherapy)
120/35 78/36 0.098
Systemic treatment (ER-based treatment) (hormonal/
hormonal+chemotherapy/chemotherapy/none)
74/52/25/3 64/25/21/4 0.185
3 years relapse-free survival rate*** 93 (2) 85 (3) 0.001
3 years cancer-specific survival rate*** 97 (1) 87 (3) o0.0001
3 years overall survival rate*** 94 (2) 84 (3) 0.001
Abbreviations: ER, oestrogen receptor; PR, progesterone receptor. *Individual deprivation categories were used in the statistical analysis, **median (range) and ***3-year survival
rate (SE).
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sThe basis of this observation is not clear. However, an elevated
C-reactive protein concentration (410mgl
 1) was seen in only
12% of patients, a proportion lower than previously seen in both
primary operable disease (approximately 20–40%) and in
advanced cancer (approximately 40–80%). This may, in part,
reflect the relatively small number of events relating to relapse-free
survival, cancer-specific and overall survival in the present
study.
It was of interest that, of the two acute-phase proteins examined
in the present study, albumin, generally considered to be a
relatively insensitive measure of the systemic inflammatory
response, had independent prognostic value, even with values
within the normal range. It has been previously shown that small
reductions in albumin concentrations are associated with certain
comorbid conditions such as liver dysfunction, cardiovascular
disease or diabetes mellitus and poorer survival in the general
population (Goldwasser and Feldman, 1997). In the present study,
only 7% of patients had such comorbidity (only one patient had
planned adjuvant treatment altered) and therefore this would
suggest that there may be an interaction between breast cancer and
albumin concentrations, which might impact on the survival of
these patients.
The mechanism by which a low serum albumin might impact on
relapse-free, cancer-specific and overall survival is not clear. It
may reflect the biological functions of circulating albumin
including binding and transporting of hormones and growth
factors, inhibition of platelet function and thrombosis (Margarson
and Soni, 1998). Furthermore, albumin in the breast cancer cell
cytosol may inhibit tumour growth (Soreide et al, 1991) and
tumour cell proliferation by modulating the activities of autocrine
growth regulatory factors (Laursen et al, 1990).
In the present study, conventional prognostic factors, including
tumour size, histological grade, nodal status and hormonal
receptor status were significant on univariate analysis. However,
including potentially curative loco-regional treatment and sys-
temic treatment based on hormonal receptor status in the
multivariate analysis, nodal status was not independently sig-
nificant. This probably reflects the close association between nodal
status and the treatment received, and their relative impact on
relapse and survival.
Nevertheless, lower albumin concentrations before surgery, even
those within the normal range, may be a sensitive measure of those
patients likely to recur and therefore be used to identify high-risk
patients and alter their treatment accordingly. Furthermore, a
follow-up measure of albumin, after the systemic inflammatory
response of treatment has resolved, may be of a value to establish
whether treatment of the primary tumour has resulted in recovery
of albumin concentrations (McMillan et al, 2003; Hilmy et al, 2005;
Jamieson et al, 2005). Clearly, further studies are required to
establish the prognostic value of preoperative albumin concentra-
tions and to determine whether longitudinal albumin concentra-
tions may also be of value.
In summary, the results of the present study suggest that
preoperative albumin concentration predicts survival, independent
of tumour-based factors, in patients undergoing potentially
curative surgery for primary operable breast cancer.
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